Exosomes for low blood counts after chemo in leukemia
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This trial tests whether umbilical cord mesenchymal stem cell exosomes can help restore blood cell counts after chemotherapy in adults with acute myeloid leukemia who are in remission. It aims to reduce the risk of infection and bleeding while waiting for bone marrow recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have acute myeloid leukemia (not a subtype called M3) and are in first complete remission after initial treatment.
- You are about to receive consolidation chemotherapy with cytarabine or a similar drug.
- Your major organs (heart, lungs, liver, kidneys) are working well enough based on standard tests.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective birth control during the study and for 6 months after.
- You have not had any other cancer treatment (chemo, radiation, immunotherapy) within the last 2 weeks, and any side effects from past treatment have mostly resolved.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This trial tests whether adding extra white blood cells (granulocytes) to a cord blood transplant can improve outcomes for people with poor-risk leukemia. It's for patients aged 16 to 55 who have certain genetic mutations or not fully responding to chemotherapy.
This trial tests an injection made from umbilical cord blood to raise low platelet counts caused by cancer therapies like chemo, immunotherapy, or radiation. It may help people with mild to moderate low platelets who haven't had recent platelet transfusions or other platelet-raising drugs.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.